Skip to content

GlobalLawDBby GenieAI

Laws Search Sanctions Map Data Developers

Search the text of the law

Log in Get an API key

Laws Search Sanctions Map Data Developers

Log in Get an API key

The Global Law Database. Free to read, built for people and AI agents.

Explore

All laws
Search the text
Sanctions
Map of connections
Compare UK and EU

Developers

AI agents (MCP)
REST API
Bulk data
API keys

Coverage

United Kingdom
European Union
United States
Canada
Australia
France
Germany
Netherlands
Spain
Austria
Norway
Finland
Switzerland
Ireland

GlobalLawDB is made by GenieAI, London. It is not legal advice: check the official text before relying on it. Text comes from official publishers under their licences, listed on the Data page.

ThemeMatch my systemLightDark

European Union
Eli Lilly and Company Ltd v Human Genome Sciences Inc (C-493/12)
Judgment
Consideration of the questions referred
31

Eli Lilly and Company Ltd v Human Genome Sciences Inc (C-493/12)

Judgment of 12 Dec 2013law://eu/cjeu/2012/c-493-12/para_31@2026-11-10

31Since no harmonised European Union patent rules are applicable in the main proceedings, the extent of the protection conferred by a basic patent can be determined only in the light of the non‑European Union rules governing patents (Medeva, paragraph 23 and the case-law cited).

Source: EUR-Lex, © European Union, 1998-2026. Reuse authorised under Decision 2011/833/EU.

Key facts

Court: Court of Justice · Third Chamber
Case: C-493/12 · ECLI:EU:C:2013:835
Decided: 12 Dec 2013
Procedure: Preliminary reference · referred by the High Court of Justice (England and Wales), Chancery Division (Patents Court) (United Kingdom)
Applicant: Eli Lilly and Company Ltd
Defendant: Human Genome Sciences Inc.
Rapporteur: C. Toader
Advocate General: N. Jääskinen
Bench: 5 judges
M. Ilešič, C.G. Fernlund, A. Ó Caoimh, C. Toader, E. Jarašiūnas
Language: English
Official: CURIA · EUR-Lex 62012CJ0493

Topics

Approximation of laws Patents

History · 1 version

12 Dec 2013Reading

Connections

Interprets 1: Regulation (EC) No 469/2009 of the European Parliament and of the Council of 6 May 2009 concerning the supplementary protection certificate for medicinal products (Codified version) (Text with EEA relevance )
Cited by 3: Teva UK Ltd and Others v Gilead Sciences Inc (C-121/17)5 provisions; Pfizer Ireland Pharmaceuticals, Operations Support Group v Orifarm GmbH (C-681/16); Arne Forsgren v Österreichisches Patentamt (C-631/13)
Cites 7: Actavis Group PTC EHF and Actavis UK Ltd v Sanofi (C-443/12); Regulation (EC) No 1610/96 of the European Parliament and of the Council of 23 July 1996 concerning the creation of a supplementary protection certificate for plant protection products; Sunshine Deutschland Handelsgesellschaft mbH v Hauptzollamt Kiel (C-229/06); Georgetown University v Octrooicentrum Nederland (C-484/12); Regulation (EU) No 1257/2012 of the European Parliament and of the Council of 17 December 2012 implementing enhanced cooperation in the area of the creation of unitary patent protection; Daiichi Sankyo Company v Comptroller General of Patents, Designs and Trade Marks (C-6/11); Regulation (EC) No 469/2009 of the European Parliament and of the Council of 6 May 2009 concerning the supplementary protection certificate for medicinal products (Codified version) (Text with EEA relevance )